Press releases

Eluvia is the first peripheral vascular interventional technology approved in U.S. to offer a sustained release of a drug to treat peripheral artery disease.

First head-to-head trial assesses effectiveness of sustained drug release in interventional treatment for patients with blockages in femoropopliteal arteries.

New data at World Congress of Endourology demonstrate the Lithovue Empower device for kidney stone retrieval improves the OR experience.

Key data will include results from IMPERIAL trial evaluating ELUVIA drug-eluting stent and from REPRISE III study evaluating LOTUS Aortic Valve System.

Acquisition expands Boston Scientific portfolio of men's health in-office procedures with SpaceOAR, an adjunctive therapy for prostate cancer patients.